PAVmed Inc
PAVM
View Detailed Chart
0.287USD
-0.013-4.23%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
6.63MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.23%
5 Days
-5.12%
1 Month
-11.10%
6 Months
-52.67%
Year to Date
-54.18%
1 Year
-56.18%
View Detailed Chart
TradingKey Stock Score of PAVmed Inc
Currency: USD Updated: 2025-12-24Key Insights
PAVmed Inc's fundamentals are relatively healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 141/206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PAVmed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
12.000
Target Price
+3362.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
PAVmed Inc Highlights
StrengthsRisks
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 694.43% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.00M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Undervalued
The company’s latest PE is -2.85, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.39M shares, increasing 19.16% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 208.37K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.27.
PAVmed Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
PAVmed Inc Info
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Ticker SymbolPAVM
CompanyPAVmed Inc
CEOAklog (Lishan)
Websitehttps://pavmed.com/
FAQs
What is the current price of PAVmed Inc (PAVM)?
The current price of PAVmed Inc (PAVM) is 0.287.
What is the symbol of PAVmed Inc?
The ticker symbol of PAVmed Inc is PAVM.
What is the 52-week high of PAVmed Inc?
The 52-week high of PAVmed Inc is 0.895.
What is the 52-week low of PAVmed Inc?
The 52-week low of PAVmed Inc is 0.272.
What is the market capitalization of PAVmed Inc?
The market capitalization of PAVmed Inc is 6.63M.
What is the net income of PAVmed Inc?
The net income of PAVmed Inc is 31.97M.
Is PAVmed Inc (PAVM) currently rated as Buy, Hold, or Sell?
According to analysts, PAVmed Inc (PAVM) has an overall rating of Buy, with a price target of 12.000.
What is the Earnings Per Share (EPS TTM) of PAVmed Inc (PAVM)?
The Earnings Per Share (EPS TTM) of PAVmed Inc (PAVM) is -0.101.
Related Instruments
+0.89%
-0.17%
+0.14%
-0.03%
+0.22%
-0.05%
-0.02%
-0.22%
-0.02%
+1.33%
+0.12%
+0.47%
-0.14%
+0.25%
+0.86%
+0.14%
+0.01%
-0.09%
+0.08%
-0.57%
